Novo Nordisk starts crucial trial of obesity tablet

While Novo Nordisk struggles to meet the demand for its injection-based treatment Wegovy in the US, the pharmaceutical company has started a phase IIIa trial of semaglutide as a tablet-based treatment for obesity, aiming for similar weight loss results.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde

On Monday, Novo Nordisk initiated a global phase IIIa trial of semaglutide in tablet form, as a treatment for obesity, the pharmaceutical company confirms to MedWatch.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading